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Available online 2 December 2015Duchenne muscular dystrophy (DMD) is a pediatric, X-linked, progressive muscle-wasting disorder caused by
loss of function mutations affecting the gene encoding the dystrophin protein. While the primary genetic insult
in DMD is well described, many details of the molecular and cellular pathologies that follow dystrophin loss are
incompletely understood. To investigate gene expression in dystrophic muscle we have applied mRNA and
microRNA (miRNA) microarray technology to themdxmouse model of DMD. This study was designed to gener-
ate a complete description of gene expression changes associatedwith dystrophic pathology and the response to
an experimental therapy which restores dystrophin protein function. These datasets have enabled (1) the deter-
mination of gene expression changes associated with dystrophic pathology, (2) identiﬁcation of differentially
expressed genes that are restored towards wild-type levels after therapeutic dystrophin rescue, (3) investigation
of the correlation betweenmRNA and protein expression (determined by parallelmass spectrometry proteomics
analysis), and (4) prediction of pathology associated miRNA-target interactions. Here we describe in detail how
the data were generated including the basic analysis as contained in the manuscript published in Human
Molecular Genetics with PMID 26385637. The data have been deposited in the Gene Expression Omnibus
(GEO) with the accession number GSE64420.
© 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).s Medical Discovery Institute,
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2.1. Experimental design
Wild-type mice (n= 3) were compared with dystrophic mdxmice
(n=4) andmdxmice treatedwith Pip6e-PMO (n=4) an experimental
therapy for Duchenne muscular dystrophy (DMD). Pip6e-PMO is a co-
valent conjugate of an arginine-rich, cell penetrating peptide (Pip6e)
with a phosphorodiamidate morpholino oligonucleotide (PMO) which
induces exclusion of exon 23 from the Dmd transcript, open reading
frame restoration, and therapeutic rescue of dystrophin protein expres-
sion [1–3]. All mice used were male and 14 weeks old at the end of
experiment. This time point was selected as it represents a period of
established pathology in the dystrophic mice.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Animal experiments were carried out in accordance to procedures
authorized by the UK Home Ofﬁce in accordance with UK law
(i.e. Animals (Scientiﬁc Procedures) Act 1986). The C57/Bl10 or C57/
Bl10ScSn-Dmdmdx/J (mdx) strains were maintained at the Biomedical
Sciences Building, University of Oxford. Treated animals were injected
with a single 12.5 mg/kg dose of Pip6e-PMO in sterile saline via the
tail vein at 12 weeks of age under isoﬂurane anesthesia. Pip6e peptide:
Ac-RXRRBRRXYRFLIRXRBRXRB-OH (where X is aminohexanoyl and B is
β-alanine) was synthesized using Fmoc chemistry and puriﬁed by
reverse-phase HPLC. Pip6e peptide was conjugated to the PMO
(5′-GGCCAAACCTCGGCTTACCTGAAAT) (Gene Tools LLC, Philomath,
OR) through an amide linkage at the 3′ end terminus. Conjugates
were puriﬁed by cation exchange HPLC, desalted, and analyzed by
MALDI-TOF MS as described previously [1]. Mice were sacriﬁced by es-
calating CO2 concentration and death conﬁrmed by cervical dislocation.
Mice were then exsanguinated via the jugular vein and blood was
collected using Microvette CB300 serum collection tubes (Sarstedt,
Leicester, UK). Tibialis anterior (TA) muscles were macrodissected and
snap frozen in liquid nitrogen-cooled isopentane. TA muscles were
mounted on cork diskswith Tissue-Tek OCT Compound (Sakura Finetek
Europe, Leiden, Netherlands) with the muscle arranged so as to be per-
pendicular to the cork. Tendinous tissue was removed by sectioning.
Fifty 8 μm cryosectionswere prepared from themid-belly of themuscle
and placedmicrocentrifuge tubes. Mountedmuscles and tubes contain-
ing sections were stored at−80 °C until ready for analysis.
2.3. RNA isolation
TRIzol reagent (Life Technologies, Paisley, UK) was added to each
tube containing muscle sections and samples homogenized using a
Precellys 24 (Bertin Technologies, France). The resulting TRIzol solution
was collected and RNA extraction continued according to
manufacturer's instructions. Samples were treated with DNase I using
the TURBODNA-free kit (Life Technologies) in order to remove genomic
DNA contamination. The RNA samples used for mRNA analysis were
further column-puriﬁed (RNeasy Mini kit, Qiagen, Manchester, UK).
Each RNA sample was analyzed using the Agilent 2100 Bioanalyzer
(Agilent Technologies, USA) to assess RNA quality. The resulting RIN
(RNA Integrity Number) values ranged from 6.3 to 8.5.
2.4. mRNA and miRNA microarray processing and statistical analysis
Labeling and hybridization were performed according to standard
Affymetrix protocols at the Affymetrix Core facility BEA, Bioinformatics
and Expression Analysis, at Karolinska Institutet, Novum, Huddinge,
Sweden. The processing and data analyses were performed in
Affymetrix Expression Console Software.
For mRNA analysis, 100 ng of column-puriﬁed total RNA was ana-
lyzed for each of the 11 samples using Mouse Gene ST 1.1 Array plates
(Affymetrix, Santa Clara, CA). The Mouse Gene ST 1.1 array covers
26,166 RefSeq transcripts. Probes are evenly distributed across the tar-
get exons with a median of 27 probes per transcript. The ST1.1 arrays
were analyzed using Median polish, RMA background correction and
Sketch-Quantile normalization (RMA-Sketch in Expression Console
Software). We only analyzed 28,350 probe sets with category “main”
(i.e. excluding technical control probe sets), according to Affymetrix
annotation. To ﬁlter out very low ﬂuorescence signal intensities we
used a cutoff of 30. Probe sets with signals below 30 in all threebiological groups were removed (15,219 probe sets remained after
ﬁltering). Unpaired 2-sided Student's t-testwas performedwith the cri-
terion for differentially expressed transcripts set to P b 0.05. False Dis-
covery Rate (FDR) estimations were performed by calculating q values
(qvalue R package) from the P-value lists.
FormiRNA analysis, 500 ng of total RNAwas analyzed for each of the
11 samples using Affymetrix GeneChip miRNA 3.0 arrays (Affymetrix,
Santa Clara, CA). The miRNA 3.0 array covers 153 organisms and con-
tains 19,724 mature miRNA probe sets; the number of probes for each
probe set is 9. For Mus musculus there is 1111 mature miRNA and 855
pre-miRNA probe sets present on the array. ThemiRNA arrays were an-
alyzed using Robust Multichip Analysis (RMA) and DABG (detected
above background). The data were ﬁltered in order to consider Mus
musculus miRNAs only (1966 probe sets remaining). Transcripts with
absent detection signals in at least three of the four replicates (or two
out of the three replicates in the controls) were removed (682 probe
sets remained after ﬁltering).
The microarray data discussed in this study have been deposited in
NCBI's Gene Expression Omnibus (3) and are accessible through GEO
Series accession number GSE64420 (mRNA data: GSE64418, miRNA
data: GSE64419).
3. Discussion
We have described the generation of high quality mRNA andmiRNA
data in themost commonly usedmousemodel of DMD. These data have
been interrogated in multiple ways, in order to further our understand-
ing of the molecular pathogenesis of DMD, characterize the response to
therapeutic dystrophin re-expression, identify novel biomarkers,
investigate the relationship between protein andmRNA expression in dys-
trophic muscle, and predict disease-relevant miRNA-target interactions.
The resulting analyses were published in our recent manuscript [4].
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